Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 8, 2022- New results demonstrate MitraClip™ transcatheter edge-to-edge repair (TEER) is effective at treating leaky valves in people with secondary mitral regurgitation (MR)- Data from the first report on patients with a pacemaker lead across the tricuspid valve show TriClip™ and TriClip G4 TEER systems significantly reduce tricuspid regurgitation (TR) and substantially improve quality of life
-
Feb 21, 2022- New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS™ HF System, a small implantable sensor that can flag early warning signs of worsening heart failure- FDA approval was supported by data from the GUIDE-HF trial, which suggested that the CardioMEMS sensor can reduce hospitalizations and improve care for more types of patients living with heart failure
- Feb 7, 2022- Abbott's investigational Aveir™ DR dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart- Proprietary implant-to-implant (i2i™) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate- Aveir DR is also specifically designed to be retrieved if therapy needs evolve
- Jan 12, 2022- EnSite™ X EP System with EnSite Omnipolar Technology (OT) provides a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise
- Nov 12, 2021-- New, late-breaking data from the Leadless II IDE study confirm the Aveir™ leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms-- Abbott's Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed-- Abbott's investigational Aveir leadless pacemaker is currently being evaluated for FDA approval
-
Nov 10, 2021- One in four physicians surveyed feel the "lack of technology or equipment to make an accurate diagnosis of coronary artery disease and peripheral artery disease" is a key obstacle to an accurate diagnosis- Over a third of surveyed patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described "confusion about what I was supposed to do next" as an important barrier to early and accurate diagnosis- Socioeconomic status, age and gender in underserved communities are contributing factors that impact patients’ access to care